Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02786173 · ClinicalTrials.gov registry record

Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"

A clinical trial, sponsored by Metro Health, Michigan.

Completed
Registry status
1,000
Enrollment target

NCT02786173: Completed study, sponsored by Metro Health, Michigan.

NCT02786173 is a clinical trial that has completed, run by Metro Health, Michigan. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02786173 has completed, sponsored by Metro Health, Michigan.

COMPLETED
Registry status
1,000 participants
Enrollment target

Study Summary

The PRIME Registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (CLI) and advanced peripheral artery disease (PAD).

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2013-01
Est. Completion 2021-11-05
Metro Health, Michigan

4 total trials

What the finished NCT02786173 record still lists

NCT02786173 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT02786173 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02786173 about?

NCT02786173 is a clinical study titled "Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"". The PRIME Registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (CLI) and advanced peripheral artery disease (PAD).

What is the current status of trial NCT02786173?

This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2013-01. Estimated completion is 2021-11-05.

Who is sponsoring clinical trial NCT02786173?

This trial is sponsored by Metro Health, Michigan, which has 4 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02786173, the US trial registry maintained by the National Library of Medicine. NCT02786173 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.